Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

764
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
764
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

521
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
521
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025

相关实验视频

Updated: Jul 17, 2025

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

罗扎诺利克西祖马布:第一次批准

Sheridan M Hoy1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|September 1, 2023
PubMed
概括

罗扎诺利克西祖马布是一种新的治疗方法,用于治疗成年人普遍性肌痛性肌痛症 (gMG). 它是美国批准用于抗乙胆受体 (AChR) 和抗肌特异性激酶 (MuSK) 抗体阳性gMG的第一种疗法.

科学领域:

  • 免疫学 免疫学 免疫学
  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 一般化肌痛性肌痛症 (gMG) 是一种罕见的自身免疫性疾病,影响神经肌肉传播.
  • 目前的治疗方法旨在控制症状,但需要新的向疗法.
  • 罗扎诺利克西祖马布向新生儿的Fc受体 (FcRn),这是免疫球蛋白G (IgG) 恒温的关键调节器.

研究的目的:

  • 总结一下rozanolixizumab的发展里程碑.
  • 为了突出其首次批准一般化肌痛性肌痛症 (gMG).
  • 提供其作用机制和目标患者群体的概述.

主要方法:

  • 开发了罗扎诺利克西祖马布,一种人性化的IgG4单克隆抗体.
  • 药物进行皮下注射.
  • 临床试验评估gMG患者的疗效和安全性.

主要成果:

  • 在2023年6月27日,Rozanolixizumab获得了美国FDA的批准,用于抗乙胆受体 (AChR) 或抗肌肉特异性激酶 (MuSK) 抗体阳性gMG的成年人.
  • 它是第一种被批准用于ACHR和MuSK抗体阳性gMG.G的药物.
  • 欧盟和日本正在进行监管审查.

更多相关视频

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.1K

相关实验视频

Last Updated: Jul 17, 2025

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.1K

结论:

  • 罗扎诺利克西祖马布 (Rozanolixizumab) 代表了gMG治疗的重大进展.
  • 它的批准为广泛的gMG患者提供了新的治疗选择.
  • 目前正在进行的开发针对其他自身免疫性疾病.